There is a lot of innovation in the US healthcare industry concerning ways to manage the care for specialty populations, but there still needs to be a way to regulate these innovative models. Matt Salo pointed out that for so long the financial incentives have not been there to get people healthy and keep them there, and meanwhile only a small part of the population accounts for half of the total costs.
“That’s the Holy Grail,” Salo said. “If we can figure out how to improve the care and bring the cost down for that group, then we’ll have figured all this out.”
Unfortunately, with all the emerging models out there, data is not being shared across boundaries and entities are caring for part of a person instead of the whole person, said Margaret E. O’Kane.
“I think the challenge is catching up with [current innovation], assessing it in a hard-nosed way, and really being able to make comparisons,” O’Kane said. “Part of the problem with a proliferation of innovation is that everybody’s doing something different and they’re all measuring it in a different way.”
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More